Mesothelioma Articles: Page 1 of 11
It takes a multidisciplinary team to treat a person with a rare disease. Along with highly experienced and accomplished medical scientists there needs to be individualized care. Included and embedded in this specialized treatment is the skills of coaching. We are all very familiar with the roles that coaches play in sports. From many different definitions some of the most successful sports coaches have mastered different skill sets. Some of the skills are analyzing performances, instructing [...]
Continue reading
For the first time in 16 years, the U.S. Food & Drug Administration has approved a new drug combination specifically for the treatment of malignant pleural mesothelioma. The two drugs, which are to be used together when surgery is not an option, are Opdivo (nivolumab) and Yervoy (ipilimumab). About 20,000 Americans are diagnosed with malignant pleural mesothelioma each year according to the FDA – the vast majority of which have tumors at diagnosis that cannot be removed by surgery. The [...]
Continue reading
Dr. Paul Baas of the Netherlands Cancer Institute and the University of Leiden in Amsterdam recently presented on the CheckMate 743 study at the International Association for the Study of Lung Cancer World Conference. The randomized phase III Checkmate 743 clinical trial prescribed mesothelioma patients who were not candidates for surgery with a combination of first-line nivolumab and ipilimumab. The promising results yielded a four-month improvement in median overall survival for patients [...]
Continue reading
Immuno-Oncology News recently published results of a Phase 2 clinical trial of the immuno-checkpoint inhibitor Imfinzi (durvalumab) for patients diagnosed with malignant pleural mesothelioma. The PrECOG cancer research group tested the effects of pairing Imfinzi, an AstraZeneca drug that blocks the activity of the PD-1 receptor in immune T-cells, with standard chemotherapy on a group of 55 individuals who had been recently diagnosed with inoperable malignant pleural mesothelioma. The [...]
Continue reading
The EJNMMI Research medical journal recently published an article entitled “FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients” that outlines a study wherein 72 patients diagnosed with malignant pleural mesothelioma (MPM) at the University Hospital Zurich underwent pre-treatment FDG PET and CT scans alongside curative treatments. In the study, Swiss researchers discovered that using machine-learning radiomics models in conjunction with PET scans to [...]
Continue reading
